Adage Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Adage Capital Partners's FDMT Position: Q3 2026 in Review
Adage Capital Partners increased its 4D Molecular Therapeutics (FDMT) stake by 1.8% in Q3 2026, buying an estimated $520K and bringing the position to 2,289,203 shares worth $32.8M. The position accounts for 0.05% of the portfolio, ranked #361.
Adage Capital Partners first reported a position in FDMT in Q3 2025 and has held it in 5 quarters since. 161 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Adage Capital Partners held 2,289,203 shares of 4D Molecular Therapeutics worth $32.8M as of Q3 2026.
- Adage Capital Partners bought 40,000 4D Molecular Therapeutics shares in Q3 2026, an estimated $520K.
- 4D Molecular Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q3 2026, its #361 holding.
- Adage Capital Partners first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 5 quarters since.
- 161 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.